Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery
Kohei Shitara(National Cancer Center Hospital East), Kei Muro(Aichi Cancer Center), Yukihide Kanemitsu(National Cancer Center), Seiji Ishiguro, Yasuhiro Shimizu(Aichi Cancer Center), Yoshitaka Inaba(Aichi Cancer Center), Chihiro Kondo, Keitaro Matsuo(Aichi Cancer Center), Hidekazu Yamaura(Aichi Cancer Center), Daisuke Takahari(The Cancer Institute Hospital), Koji Komori(Aichi Cancer Center), Takashi Ura(Aichi Cancer Center), Tsuyoshi Sano(Aichi Medical University), Mina Kato(Aichi Cancer Center), Yozo Sato(Aichi Cancer Center)
Cited by 4
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k